Pfizer expects $32 billion in revenue from its Covid-19 vaccines in 2022, as its annual profits for 2021 have more than doubled to $22 billion.
It also expects $22 billion in sales for 2022 from Paxlovid, the company's Covid-19 pill.
The pharmaceutical giant, which with German company BioNTech received approval for the first vaccine to treat the deadly virus, recorded annual revenue in 2021 nearly double that of 2020 at $81.3 billion, with $36.8 billion coming from the Covid-19 vaccine.
The results show how coronavirus has transformed Pfizer, which a year ago had projected just $15 billion in revenue from the vaccine. dollars in Covid-19 vaccine sales for 2021 and ended up selling twice as much as that
(CNA)
CNA - French News Agency
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
